Krystal Biotech to Present at Upcoming Scientific Conferences

Rhea-AI Summary

Krystal Biotech (NASDAQ: KRYS) has announced its participation in multiple scientific conferences during May and June 2025, showcasing developments across lung, eye, and skin programs.

Key presentations include:

• An oral presentation on HSV-1 vector systems for respiratory tissues at the ASGCT 28th Annual Meeting on May 17
• A poster presentation on KB707 immunotherapy for lung tumors at ASCO Annual Meeting on June 2
• Research on KB801 gene therapy for corneal wounds at ARVO 2025 on May 5
• Findings on HSV-1-based gene therapy for Hailey-Hailey and Darier diseases at SID 2025 on May 9

All presentation materials will be made available on the company's investor relations website after the conferences.

PITTSBURGH, April 24, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs in the lung, eye, and skin at upcoming scientific conferences being held in May and June.

Presentation details are outlined below.

American Society of Gene & Cell Therapy (ASGCT) 28^th Annual Meeting
Invited Oral Presentation

• Title: HSV-1 as a vector system for targeting respiratory tissues in genetic pulmonary disease
• Presenter: Trevor Parry, PhD
• Date and Time: May 17, 2025 at 8:50AM CT
  

2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Poster Presentation

• Title: Inhaled KB707, a novel HSV-based immunotherapy, as a monotherapy in patients with advanced solid tumor malignancies affecting the lungs: Efficacy and safety results from a phase 1/2 study
• Presenter: Wen Wee Ma, MD, Enterprise Vice Chair, Research, Cancer Institute, Cleveland Clinic
• Date and Time: June 2, 2025 from 1:30PM to 4:30PM CT
• Poster Session or Category: Developmental Therapeutics – Immunotherapy
• Abstract Number: 2575
• Poster Bd Number: 222

Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
Poster Presentation

• Title: Topical application of the HSV-1-based gene therapy vector KB801 results in sustained nerve growth factor expression in wounded murine corneas
• Presenter: Haley Cartwright, PhD
• Date and Time: May 5, 2025 from 3:00PM to 4:45PM MT
• Poster Session or Category: 258 – Preclinical Therapeutics
• Poster Number: B0154
  

Society for Investigative Dermatology (SID) 2025 Annual Meeting
Poster Presentation

• Title: Expansion of an HSV-1-based gene therapy platform to treat Hailey-Hailey and Darier diseases
• Presenter: Bruce Nmezi, PhD
• Date and Time: May 9, 2025 from 4:30PM to 6:00PM PT
• Poster Session or Category: Genetic Disease, Gene Regulation, Gene Therapy & Epigenetics
• Poster Number: 0554
  

Additional presentation details will be available to conference attendees. Following completion of each conference, presentation slides or posters, as applicable, will also be available to view online on the Investor section of the Company’s website.

About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK^® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).

CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com

FAQ

What breakthrough treatments will Krystal Biotech (KRYS) present at ASCO 2025?

Krystal Biotech will present data on KB707, an inhaled HSV-based immunotherapy for advanced solid tumor malignancies affecting the lungs, showing efficacy and safety results from a phase 1/2 study.

What is the focus of Krystal Biotech's (KRYS) presentation at ASGCT 2025?

The company will present on HSV-1 as a vector system for targeting respiratory tissues in genetic pulmonary disease on May 17, 2025.

What eye-related research is Krystal Biotech (KRYS) presenting at ARVO 2025?

They will present research on KB801, an HSV-1-based gene therapy vector that shows sustained nerve growth factor expression in wounded mouse corneas.

What skin conditions is Krystal Biotech (KRYS) targeting with their gene therapy platform?

At SID 2025, Krystal Biotech will present their HSV-1-based gene therapy platform's application for treating Hailey-Hailey and Darier diseases.

When will Krystal Biotech's (KRYS) conference presentations become publicly available?

The presentation slides and posters will be available on the Investor section of the company's website after the completion of each conference.